全文获取类型
收费全文 | 2128篇 |
免费 | 203篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 85篇 |
妇产科学 | 30篇 |
基础医学 | 225篇 |
口腔科学 | 9篇 |
临床医学 | 178篇 |
内科学 | 618篇 |
皮肤病学 | 14篇 |
神经病学 | 258篇 |
特种医学 | 58篇 |
外科学 | 399篇 |
综合类 | 17篇 |
预防医学 | 173篇 |
眼科学 | 22篇 |
药学 | 132篇 |
中国医学 | 2篇 |
肿瘤学 | 96篇 |
出版年
2023年 | 10篇 |
2022年 | 7篇 |
2021年 | 26篇 |
2020年 | 22篇 |
2019年 | 43篇 |
2018年 | 43篇 |
2017年 | 47篇 |
2016年 | 35篇 |
2015年 | 75篇 |
2014年 | 76篇 |
2013年 | 99篇 |
2012年 | 141篇 |
2011年 | 126篇 |
2010年 | 87篇 |
2009年 | 60篇 |
2008年 | 112篇 |
2007年 | 105篇 |
2006年 | 124篇 |
2005年 | 80篇 |
2004年 | 68篇 |
2003年 | 69篇 |
2002年 | 74篇 |
2001年 | 69篇 |
2000年 | 64篇 |
1999年 | 67篇 |
1998年 | 33篇 |
1997年 | 16篇 |
1996年 | 19篇 |
1995年 | 19篇 |
1994年 | 9篇 |
1993年 | 20篇 |
1992年 | 57篇 |
1991年 | 47篇 |
1990年 | 49篇 |
1989年 | 51篇 |
1988年 | 49篇 |
1987年 | 32篇 |
1986年 | 35篇 |
1985年 | 32篇 |
1984年 | 20篇 |
1983年 | 31篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1979年 | 17篇 |
1977年 | 5篇 |
1974年 | 6篇 |
1973年 | 4篇 |
1972年 | 5篇 |
1968年 | 6篇 |
1967年 | 4篇 |
排序方式: 共有2335条查询结果,搜索用时 31 毫秒
1.
2.
David B Karpf Susanne Pihl Sanchita Mourya Eva Mortensen Eshwari Kovoor Denka Markova Jonathan A Leff 《Journal of bone and mineral research》2020,35(8):1430-1440
TransCon PTH is a sustained-release, essentially inactive prodrug transiently bound to an inert carrier, designed to release PTH(1-34), and in development for hypoparathyroidism (HP). This phase 1, randomized, placebo-controlled, single and multiple ascending dose (SAD and MAD, respectively) trial evaluated safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of TransCon PTH in healthy adults. SAD and MAD cohorts consisted of 10 subjects (eight active, two placebo) who received up to seven single or six multiple ascending doses of TransCon PTH, respectively. TransCon PTH doses ranged from 3.5 to 124 μg PTH(1-34) for the SAD cohorts and 3.5 to 24 μg PTH(1-34)/day for the MAD cohorts. The primary PK endpoint was Free PTH. The PD endpoints included albumin adjusted serum calcium (sCa), fractional excretion of calcium (FECa), intact endogenous PTH(1-84), bone turnover markers, renal tubular maximum reabsorption of phosphate/glomerular filtration rate (TMP/GFR), serum phosphate (sP) and magnesium, and 1,25 dihydroxyvitamin D. TransCon PTH was generally well tolerated; there were no drug-related serious adverse events (SAEs), and all AEs were transient in nature. Free PTH demonstrated an effective half-life of approximately 60 hours and a dose-dependent, sustained exposure with an infusion-like profile within the calculated physiologic range for active PTH at steady-state. Albumin-adjusted sCa demonstrated a dose-dependent, sustained response with complete control of FECa despite modest hypercalcemia at higher doses. Renal tubular maximum reabsorption of phosphate/glomerular filtration rate (TMP/GFR) showed a dose-dependent decrease, resulting in a dose-dependent decrease in sP. TransCon PTH administered daily for 10 days showed no increase in the osteoblastic bone formation markers, serum bone-specific alkaline phosphatase (BSAP) or P1NP, or the osteoclastic bone resorption marker, urine NTx, but modestly and transiently increased the osteoclast marker, serum CTx. These phase 1 data support TransCon PTH as a daily replacement therapy for HP providing physiological levels of PTH 24 hours per day and advancement into phase 2 clinical development. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research. 相似文献
3.
Low myocardial glucose uptake in Turner syndrome is unaffected by growth hormone: a randomized,placebo‐controlled FDG‐PET study 下载免费PDF全文
4.
Marilyn Katz Nicole Silverstein Patrick Coll Gail Sullivan Eric M. Mortensen Adam Sachs Jeffrey B. Gross Eric Girard Joy Liang Benjamin T. Ristau Christina Stevenson Phillip P. Smith Brian D. Shames Ryan Millea Irfan Ali Constantine M. Poulos Akila B. Ramaraj Azuka Onye Otukoya David W. McFadden 《Current problems in surgery》2019,56(7):260-329
5.
6.
7.
8.
9.
S. U. Thorsen S. Eising H. B. Mortensen K. Skogstrand F. Pociot J. Johannesen J. Svensson the Danish Childhood Diabetes Registry 《Scandinavian journal of immunology》2014,80(6):452-461
The mechanisms by which antigen‐specific T cells migrate to the islets of Langerhans in type 1 diabetes (T1D) are largely unknown. Chemokines attract immune cells to sites of inflammation. The aim was to elucidate the role of inflammatory chemokines in T1D at time of diagnosis. From a population‐based registry of children diagnosed with T1D from 1997 to 2005, we studied five different inflammatory chemokines (CCL2, CCL3, CCL4, CCL5 and CXCL8). Four hundred and eighty‐two cases and 479 sibling frequencies matched on age and sample year distribution were included. Patients showed lower levels of CCL4 compared to siblings, but this result was not significant after correction for multiple testing. CCL2, CCL3, CCL4 and CXCL8 levels were highest in the most recent cohorts (P < 0.01) in both patients and siblings. A significant seasonal variation – for most of the chemokines – was demonstrated with the highest level during the summer period in both patients and siblings. In addition, there was a significant inverse relationship between CCL4 levels and age. When comparing patients and siblings, remarkably few differences were identified, but interestingly chemokine levels varied with age, season and period for the entire study population. Such variations should be taken into account when studying chemokines in paediatric populations. 相似文献
10.
R. G. Hall II PharmD MSCS A. T. Blaszczyk PharmD K. A. Thompson PharmD S. D. Brouse PharmD C. A. Giuliano PharmD C. R. Frei PharmD MSc N. A. Forcade PharmD MSc E. M. Mortensen MD MSc T. Bell MD R. J. Bedimo MD MSc C. A. Alvarez PharmD MSc 《Journal of clinical pharmacy and therapeutics》2014,39(6):653-657